Several transcription factors orchestrate the adipocyte differentiation process (reviewed in references 9, 13, and 43). These include the nuclear receptor peroxisome proliferatoractivated receptor ␥ (PPAR␥) (46, 47) , the family of CCAAT enhancer binding proteins (C/EBP) (8, 15, 16, (53) (54) (55) , and the basic helix-loop-helix leucine zipper transcription factor adipocyte differentiation and determination factor 1 (ADD-1) (21, 48) , which was independently cloned as the sterol regulatory element binding protein 1 (SREBP-1), based on its role in cholesterol homeostasis (56) . Current data suggest that C/EBP␤ and -␦ induce the expression of PPAR␥ (33, 54) , which then triggers the adipogenic program. Terminal differentiation appears to require the concerted action of PPAR␥, C/EBP␣, and ADD-1/SREBP-1 (21, 48) . Several arguments support the important role of PPAR␥ in adipocyte differentiation. First, ectopic expression of PPAR␥ is sufficient to induce adipocyte conversion of fibroblasts (46, 47) . In addition, PPAR␥ together with C/EBP␣ can induce transdifferentiation of myoblasts into adipocytes (19) . Second, the description of functional peroxisome proliferator-responsive elements (PPREs) in the regulatory sequences of several of the genes which are induced during adipocyte differentiation, such as the genes coding for adipocyte fatty acid binding protein aP2 (46) , phosphoenolpyruvate carboxykinase (45) , acyl coenzyme A (CoA) synthetase (36, 37) , and lipoprotein lipase (35) , is consistent with the crucial role attributed to PPAR␥ in lipid metabolism. Finally, prostaglandin J2 derivatives, certain nonsteroidal anti-inflammatory drugs, and antidiabetic thiazolidinediones, which have been identified as natural and synthetic PPAR␥ ligands, respectively (5, 14, (23) (24) (25) 51) , all induce or enhance adipocyte differentiation (2, 3, 7, 14, 23, 24, 29, 47) .
The identification of thiazolidinediones as PPAR␥ ligands together with the central role which adipose tissue plays in the pathogenesis of important metabolic disorders, such as obesity and non-insulin-dependent diabetes mellitus, has generated a major drive to understand the regulation of PPAR␥ gene expression. Since ADD-1/SREBP-1 and PPAR␥ both are important during adipocyte differentiation, we analyzed PPAR␥ expression in cells ectopically expressing ADD-1/SREBP-1. Increased levels of PPAR␥ mRNA and protein were found under these conditions. SREBP-2 had similar effects on PPAR␥ expression. It was furthermore shown that PPAR␥ expression was influenced by cellular cholesterol levels in cells of both hepatic and adipocyte origin, an effect mediated by the SREBP family of transcription factors. The control of PPAR␥ expression by the SREBP family of transcription factors is mediated through two sequence elements. First, there is a functional E-box in the PPAR␥1 promoter. In addition, we also describe a functional E-box element located upstream of the exon A2 of the human PPAR␥ gene, in the recently described PPAR␥3 promoter (12) . These observations suggest that regulatory interactions between the SREBPs and PPAR␥ can coordinate cholesterol and fatty acid metabolism.
MATERIALS AND METHODS

Materials and oligonucleotides.
The oligonucleotides used for various experiments in this report are listed in Table 1 . BRL 49,653 and simvastatin were kind gifts of A. Nazdan of Ligand Pharmaceuticals and S. Wright from Merck Re-search Laboratories, respectively. All other chemicals, unless stated otherwise, were purchased from Sigma (St. Louis, Mo.).
Cell culture and retroviral infections. Standard cell culture conditions were used to maintain 3T3-L1 (obtained from American Type Culture Collection [ATCC]), HeLa (ATCC), RK-13 (ATCC), CCL-39 (a kind gift from Claude Sardet), and HepG2 cells (ATCC). BRL 49,653 and simvastatin were dissolved in dimethyl sulfoxide, and cholesterol and 25-hydroxycholesterol, linoleic acid, and linolenic acid were dissolved in ethanol. Prior to addition to cells, the fatty acids were complexed to bovine serum albumin (37) . Control cells received vehicle only. Retroviral infection of 3T3-L1 cells was performed as described previously (21) . Briefly, the BOSC23 cell line was transiently transfected with the recombinant retroviral vectors pBabe, ADD-1 403, and ADD-1 (21) by the calcium phosphate method. Viral supernatants were collected 48 h after transfection and titrated. 3T3-L1 cells were incubated with retrovirus for 5 h in the presence of 4 g of Polybrene per ml. Cells were then subcultured (1:3) for 2 days after infection in medium containing puromycin (2 g/ml) for selection. Differentiation of 3T3-L1 cells was performed as described previously (26) .
RNA isolation and RNase protection assays. Total cellular RNA was prepared as described previously (32) . Human and mouse PPAR␥ (hPPAR␥ and mPPAR␥, respectively) mRNA levels were determined by RNase protection assay with the templates previously described (12) .
Western blot analysis of PPAR␥. Protein extraction, sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and electrotransfer were performed as described previously (11) . The membranes were blocked overnight in blocking buffer (20 mM Tris, 100 mM NaCl, 1% Tween 20, 10% skim milk). Filters were first incubated for 4 h at 21°C with either a rabbit immunoglobulin G (IgG) anti-mPPAR␥ (10 mg/ml) (11) or a rabbit IgG anti-mSREBP-1 antibody (Santa Cruz, Biotechnology, Calif.) and then for 1 h at 21°C with a goat antirabbit IgG (whole molecule) peroxidase conjugate diluted at 1/5,000. The complex was visualized with 4-chloro-1-naphthol as a reagent.
Analysis of promoter activity and transactivation assays. The PAC clone P-8856 (11), containing the full-length PPAR␥ gene, was sequenced with the oligonucleotides LF-60 and LF-63 pointing upstream of exon A2. An 800-bp fragment of the PAC clone 8856 was isolated by PCR with the amplimers LF-60 (binding to the antisense strand in exon A2) and LF-68 (binding sense at position Ϫ800 of the PPAR␥3 promoter). This PCR fragment was sequenced, inserted into the EcoRV site of pBluescript SK(ϩ) (Stratagene, La Jolla, Calif.), and, after SpeI and KpnI restriction, subcloned into pGL3 (Promega, Madison, Wis.), creating the reporter vector pGL3␥3p800. For the construction of the reporter vector pGL3␥1p2000, the previously described pGL3␥1p3000 (11) was shortened by 1 kb at its 5Ј end by digestion with KpnI and PmlI. The reporter pGL3␥2p1000 was described previously (11) . Site-directed mutagenesis of the E-box in the PPAR␥3 promoter and the E-box in the PPAR␥1 promoter was performed by splicing overlapping ends PCR (18) , with the oligonucleotide pairs LF-106/LF-60 and LF-107/LF-68, to generate the plasmid pGL3␥3p800-E-box mut , and the oligonucleotide pairs LF-145/LF-143 and LF-146/LF-144, to generate the plasmid pGL3␥1p2000-E-box mut . This changed the three bases underlined in the sequence of the ␥3 promoter 5Ј-ATTCATGTGACAT-3Ј to 5Ј-ATTCATGCAT CAT-3Ј and the bases underlined in the sequence of the ␥1 promoter 5ЈAGGA TCACTTGAGCCC3Ј to 5ЈAGGATGCATTGAGCCC3Ј. The J3-TK-Luc (49) and ACO-TK-Luc (30) luciferase reporter vectors and the expression vectors encoding for ADD-1, a dominant-negative form of ADD-1, and SREBP-1a (48, 56) were described before. Transfections, luciferase, and ␤-galactosidase assays were performed as described previously (37) . To analyze the effect of cholesterol depletion in transfection experiments, the cells were divided into two pools after transfection. Half of the transfected cells were incubated with delipidated medium, whereas the other half of the cells were incubated with the same medium supplemented with a mixture of cholesterol (10 M) and 25-hydroxycholesterol (1 M).
Electrophoretic mobility shift assays (EMSAs) and oligonucleotide sequences. SREBP-1a protein was produced in a baculovirus system, and ADD-1 was produced by in vitro transcription. The quality of the proteins was verified by SDS-PAGE. Proteins were incubated for 15 min on ice in a total volume of 20 l with 2.5 g of poly(dI-dC), 1 g of herring sperm DNA, and 1 ng of T4-polynucleotide kinase end-labelled double-stranded oligonucleotide corresponding either to the PPAR␥1-E-box (LF-141) or the PPAR␥3-E-box (LF-102) in binding buffer (10 mM Tris-HCl [pH 7.9], 40 mM KCl, 10% glycerol, 0.05% Nonidet P-40, 1 mM dithiothreitol). For competition experiments, increasing amounts of cold double-stranded oligonucleotides (10-, 50-, and 100-fold molar excess) corresponding to the PPAR␥1-E-box, the PPAR␥3-E-box, the consensus 3-hydroxy-3-methylglutaryl (HMG)-CoA synthase sterol response element (SRE) site (42) , or the mutated PPAR␥1-E-box (LF-143) and PPAR␥3-E-box (LF-106) were included just before addition of labelled oligonucleotide. DNAprotein complexes were separated by electrophoresis on a 4% polyacrylamide gel in 0.25 ϫ Tris-borate-EDTA buffer at 4°C (17) .
RESULTS
Ectopic expression of ADD-1/SREBP-1 or SREBP-2 induces PPAR␥ mRNA expression. In view of the adipogenic effects of ADD-1/SREBP-1, we investigated a potential role of ADD-1/ SREBP-1 in the expression of the PPAR␥ gene. For that purpose, HepG2 cells were electroporated with vectors expressing either SREBP-1a (56), ADD-1 (48), or SREBP-2 (20) . RNA was extracted 48 h after transfection and analyzed by RNase protection assay for the presence of the PPAR␥1 and PPAR␥3 mRNAs. PPAR␥1 mRNA levels were, as expected, the most abundant and were eight-, six-, and eightfold higher in the cells transfected with SREBP-1a, ADD-1, or SREBP-2, respectively ( Fig. 1A , lanes 2 to 4). The same degree of induction was observed when the PPAR␥3 mRNA levels were quantified. No induction of either PPAR␥1 or -3 mRNAs was detected in cells transfected with an empty expression vector (Fig. 1A , lane 1). When a separate probe, designed to specifically detect PPAR␥2 mRNA, was used in RNase protection assays, no changes in its mRNA levels were detected after transfection with either ADD-1/SREBP-1 or SREBP-2 (data not shown).
To study the effects of ADD-1 on PPAR␥ expression in more detail and in the context of adipocyte differentiation, 3T3-L1 cells were infected with either an empty retroviral vector, pBabe, or the same vector encoding full-length ADD-1 or the superactive ADD-1 403. Northern blot analysis showed that retroviral infection, by the virus encoding ADD-1, resulted in a twofold higher level of ADD-1 expression (data not shown). Infected cells were then cultured to confluence and consecutively treated with differentiation medium. Total RNA was isolated at confluence (preadipocytes) and at day 6 after confluence (adipocytes). The RNase protection assay indicated that the expression of PPAR␥ mRNA was induced in both 3T3-L1 preadipocytes (threefold) and adipocytes (sevenfold) which ectopically express ADD-1 relative to cells which express the empty pBabe vector (Fig. 1B) . Interestingly, a truncated form, ADD-1 403, equivalent to the proteolytically activated protein, which lacks the membrane-anchoring domain, was twofold more active in inducing PPAR␥ expression in undifferentiated preadipocytes (Fig. 1B) . These results suggest that the adipogenic effects of ADD-1/SREBP-1 previously demonstrated are at least in part due to an up-regulation of the PPAR␥ gene expression.
PPAR␥ protein expression is induced in cells grown under conditions which stimulate the activation of the SREBPs. In order to evaluate the possibility that PPAR␥ was induced under more physiological conditions, associated with activation of the activation of SREBPs, we quantitated the relative expression of PPAR␥ protein by Western blot analysis in undifferentiated 3T3-L1 cells ( Fig. 2A ) and HepG2 cells (Fig. 2B ) grown in medium containing different cholesterol concentrations (50) . In both cell lines, PPAR␥ protein was induced at least ninefold upon cholesterol depletion during 24 h, a condition known to enhance the production of mature and active (Fig. 2C) . Interestingly, PPAR␥ protein levels were decreased acutely by readdition of cholesterol (10 M) and 25-hydroxycholesterol (1 M) to the culture medium for 6 h ( Fig. 2A and B, lane 3) . In order to elucidate if the observed effects of cholesterol depletion on PPAR␥ expression were mediated by ADD-1/ SREBP-1, the same experiment was performed with the hamster lung cell line CCL-39 transfected with the constitutively active form of ADD-1, ADD-1 403. As expected, PPAR␥ expression was induced sixfold in the cells transfected with ADD-1 403 (Fig. 2D, lane 2) . No further changes in the expression of PPAR␥ could be observed when cells were exposed to cholesterol-depleted medium (Fig. 2D, lane 3) . As expected, in view of the cotransfection of ADD-1 403, no further reduction in PPAR␥ levels was observed upon readdition of cholesterol to the medium. PPAR␥ expression hence seems subject to a tight and fast control by alterations in intracellular cholesterol levels, and this effect is mediated by the SREBP family of transcription factors.
PPAR␥ protein expression is induced in cells treated with HMG-CoA reductase inhibitors and is not affected by fatty acids. Treatment with HMG-CoA reductase inhibitors, which block the enzyme responsible for the rate-limiting step of cholesterol synthesis, provide another way to modify cellular cholesterol levels. Upon treatment with compounds such as compactin (mevastatin) or simvastatin, cells will become cholesterol depleted and the production of the active forms of ADD-1/SREBP-1 will increase (31, 40) . Therefore, the expression of PPAR␥ protein was evaluated in HepG2 cells before and after treatment with the potent HMG-CoA reductase inhibitor simvastatin. Treatment of the cells with simvastatin (5 ϫ 10 Ϫ7 M) for 6 h resulted in a robust and fast induction of PPAR␥ protein levels (eightfold), which was sustained 12 h after addition (Fig. 3A) , further supporting the notion that cellular cholesterol levels influence the expression of PPAR␥.
Since polyunsaturated fatty acids have been reported to decrease the expression of promoters under the control of SREBP (44, 52) , we analyzed whether the induction of PPAR␥ protein expression upon cholesterol depletion was affected by the presence of fatty acids in the culture medium. As expected, when 3T3-L1 cells were incubated under lipid-free conditions, a significant induction of the levels of PPAR␥ protein was observed (Fig. 3B, lane 2) . Surprisingly, and in contrast to previous reports in the literature (44, 52) , PPAR␥ protein levels were not down-regulated when a mixture of linoleic and linolenic acids (150 M each) was added to the lipid-depleted medium (Fig. 3B, lane 3) .
Regulatory effect of ADD-1/SREBP-1 and SREBP-2 on the hPPAR␥1 and -3 promoters. To investigate the possibility of a direct transcriptional effect of the SREBPs on PPAR␥ expression, we analyzed the 5Ј upstream regulatory sequences of the human PPAR␥ gene which we have previously determined (11) . Therefore, we transfected CCL-39 cells with the pGL3␥1 p2000, pGL3␥2p1000, and pGL3␥3p800 reporter plasmids (11) , which contain, respectively 2 kb, 1 kb, and 800 bp of the human PPAR␥1, -2, and -3 promoters. The activity of the pGL3␥1p2000 and pGL3␥3p800 reporter constructs was induced at least threefold when the ADD-1/SREBP-1 expression vector was cotransfected, suggesting that the increase in PPAR␥ mRNA levels mentioned above was mediated by an effect on the proximal PPAR␥1 and -3 promoters (Fig. 4A) . Interestingly, whereas the activity of the pGL3␥1p2000 plasmid was significantly induced by ADD-1/SREBP-1, no such induction was observed with pGL3␥1p3000, which contains an additional 1,000 bp at it's 5Ј end, which suggests the presence of an inhibitory element in this region (data not shown). The activities of the PPAR␥1 and -3 promoters were induced to a similar extent (at least threefold) when an expression vector for SREBP-2 was cotransfected instead of ADD-1/SREBP-1 or when cells were exposed to cholesterol-depleted medium (Fig. 4A) . Consistent with our mRNA data, no effect of either cotransfection of ADD-1/SREBP-1 or SREBP-2 or cholesterol depletion could be observed on PPAR␥2 promoter activity.
ADD-1/SREBP-1 controls the hPPAR␥ expression through E-box motifs in the ␥1 and ␥3 promoters. In order to investigate whether the induction of PPAR␥1 and -3 expression was the consequence of direct binding of the SREBPs to the PPAR␥1 and -3 promoters, a detailed computer-assisted sequence homology analysis was performed. Potential binding sites for the SREBP transcription factor family, corresponding to putative E-box motifs, were detected in both the PPAR␥1 and PPAR␥3 promoters (see Fig. 4B for the scheme) . In order to demonstrate direct binding of ADD-1/SREBP-1 to the putative PPAR␥1-E-box (at position Ϫ1535 from the transcription initiation site 5Ј of the exon A1) and the PPAR␥3-E-box (at position Ϫ341 from the transcription initiation site 5Ј of the A2 exon), we used double-stranded oligonucleotides corresponding to the PPAR␥1-E-box (LF-141) and PPAR␥3-E-box (LF-102) as probes in EMSAs. Baculovirus-produced and partially purified SREBP-1a, a different splice variant of the ADD-1/SREBP-1 gene, is capable of binding to both sites. Competition gel shift assays using increasing amounts of cold double-stranded oligonucleotides containing either the sites mentioned above (PPAR␥1-E-box [ Fig. 5A ] or PPAR␥3-E-box [ Fig. 5C]) , the consensus SRE of the HMG-CoA synthase gene (42) , or the mutated PPAR␥1-E-box mut (from AGGATCACT TGAGCCC to AGGATGCATTGAGCCC) and PPAR␥3-Ebox mut (from ATTCATGTGACAT to ATTCATGCATCAT), were performed next in order to demonstrate the specificity of the binding (Fig. 5A and C) . Binding of SREBP-1a to the PPAR␥1-E-box is competed by both the cold PPAR␥1-E-box (Fig. 5A, lanes 2 to 3) and by the consensus SRE oligonucleotides (Fig. 5A, lanes 5 and 6) , whereas the mutated PPAR␥1-E-box mut oligonucleotide was unable to compete with the PPAR␥1-E-box for binding of SREBP-1a (Fig. 5A, lanes 8  and 9) . Similarly, cold PPAR␥3-E-box and the consensus SRE oligonucleotides were able to compete for the binding of SREBP-1a to the PPAR␥3-E-box probe (Fig. 5C , lanes 2 to 4 and 5 to 7), whereas the mutated PPAR␥3-E-box mut was not (Fig. 5C, lanes 8 to 10) . Similar EMSA results were obtained when SREBP-2 was used (data not shown).
To unequivocally demonstrate that it is through binding to the PPAR␥1-E-box and PPAR␥3-E-box that ADD-1/ SREBP-1 and SREBP-2 stimulate the activity of the hPPAR␥1 and -3 promoters, we substituted, respectively, three bases in the PPAR␥1-E-box (Fig. 5B ) and in the PPAR␥3-E-box (Fig. 5D ) in the context of the native PPAR␥1 and -3 promoters to generate the pGL3␥1p2000-E-box mut and pGL3␥3p800-E-box mut reporter plasmids. In contrast to the wild-type reporter vectors (Fig. 6A) , cotransfected ADD-1/SREBP-1 or SREBP-2 was unable to stimulate the activity of the mutated pGL3␥1p2000-E-box mut and pGL3␥3p800-E-box mut reporter vectors in the CCL-39 lung-derived cell line (Fig. 6B) .
PPAR␥ activity is stimulated by activation of ADD-1/ SREBP-1. Next we assessed whether the changes in endogenous PPAR␥ expression mentioned above, induced by modulating the cholesterol concentration in the medium, were associated with altered expression of a PPRE-driven reporter gene. We transfected the J3-TK-Luc luciferase reporter gene, which contains three copies of the PPRE of the apolipoprotein A-II gene J site (49) , into rabbit kidney-derived RK-13 cells and maintained half of the cells in cholesterol-depleted medium, whereas the other half were grown in the same medium supplemented with a mixture of cholesterol and 25-hydroxycholesterol. Under both conditions, increasing amounts of the synthetic PPAR␥ ligand BRL 49,653 were added to the medium, resulting in a dose-dependent activation of promoter activity by BRL 49,653 (Fig. 7A) . Under conditions of choles- terol depletion, the reporter gene was, however, activated to a significantly higher level. In fact, the BRL 49,653 dose-response curve was shifted proportionally, keeping the slope constant and suggesting that the observed effect of cholesterol depletion was the result of increased expression of the PPAR␥ protein. Similar results were obtained when 3T3-L1 (Fig. 7B ) and ob-1771 preadipocyte cells were used (data not shown). Consistent with the effect of synthetic PPAR␥ agonists, addition of the fatty acid linolenic acid (C 18:3 at 400 M) to the medium resulted in a roughly similar fold of induction of the PPRE-driven reporter gene in cholesterol-depleted or cholesterol-containing medium (Fig. 7C) . In order to exclude the possibility that the observed effect was specific for the apolipoprotein A-II PPRE, we performed a cotransfection experiment with a different luciferase reporter driven by a single copy of the PPRE from the acyl CoA oxidase (ACO) gene (ACO-TK-Luc [30] ). Also, the activity of the ACO-TK-Luc reporter was significantly induced by cholesterol depletion (Fig. 7D) .
DISCUSSION
PPAR␥ has been identified as one of the key factors controlling adipocyte differentiation (6, 13) . Full differentiation of preadipocytes into adipocytes is regulated by a complex interplay of the C/EBP family, the PPAR␥ proteins, and ADD-1/ SREBP-1 (13) . Although it has been reported that C/EBP␣, ADD-1/SREBP-1, and PPAR␥ by themselves can promote adipocyte differentiation, an orchestrated action of all these factors is most likely required to trigger adipocyte differentiation effectively. We demonstrated here that ADD-1/SREBP-1 and SREBP-2 directly control the expression of the human PPAR␥ gene at a transcriptional level.
ADD-1/SREBP-1 and SREBP-2 have a dual specificity in DNA binding and have been shown to be capable of interacting both with E-box sequences and SREs (21) . EMSAs and cotransfection assays demonstrated that the ADD-1/SREBP-1 family of transcription factors can stimulate the expression of the PPAR␥1 promoter and the expression of the recently cloned PPAR␥3 promoter through binding to E-box motives which are present in both promoters. Previously it has been shown that ectopically expressed ADD-1/SREBP-1 can increase the number of fibroblasts undergoing adipocyte differentiation (reference 21 and unpublished data). Our data suggest that one of the mechanisms by which ADD-1/SREBP-1 might exert its adipogenic action is through the induction of PPAR␥ expression, which in its turn will induce the expression of downstream adipocyte target genes (Fig. 7) . This hence suggests that the ADD-1/SREBP-1 family might function as proximal regulatory factors relative to PPAR␥ in the induction of adipocyte differentiation. Furthermore, the induction of PPAR␥ expression and consequent stimulation of lipogenesis could contribute to the massive cholesterol and fatty acid accumulation seen in the livers of animals overexpressing the mature form of SREBP-1a (38) and the more moderate fatty acid accumulation observed in animals overexpressing SREBP-1c (39) . Interestingly, the observation that transgenic mice overexpressing SREBP-1c, under the control of the adipose tissue-specific aP2 promoter, are lipodystrophic (41) and suggests that SREBP-1c under certain conditions could negatively influence adipogenesis. The differences between this last study (41) and previous work (21, 38, 39) , as well as our present data, are most likely explained by differential effects SREBP-1c might have at different steps during the development of adipose tissue (11a) .
In addition to the transcriptional induction of PPAR␥, ADD-1/SREBP-1 induces the expression of several important genes involved in lipogenesis in the adipocyte, such as fatty acid synthase (4, 21, 38) , acetyl CoA carboxylase (27, 38) , glycerol-3-phosphate acyltransferase (10) , and the lipoprotein lipase gene (21, 33a, 38) . These ADD-1/SREBP-1 target genes control important steps in fatty acid metabolism, which may lead to the production of natural fatty acid-derived PPAR ligands and activators, suggesting a second more indirect pathway by which ADD-1/SREBP-1 regulates adipocyte differentiation (i.e., by controlling the production of natural activators of PPAR␥) (22) (Fig. 8) . Besides this important regulatory effect of cholesterol and the ADD-1/SREBP-1 family of transcription factors on fatty acid metabolism, fatty acids were recently also reported to inhibit the maturation of ADD-1/ SREBP-1 and decrease the expression of promoters driven by sterol regulatory elements (44, 52) . Interestingly, we did not observe an effect of unsaturated fatty acids on the induction of PPAR␥ expression by cholesterol depletion (Fig. 3B) . Furthermore, fatty acids were like thiazolidinediones capable of fur- FIG. 6 . The PPAR␥1-E-box and the PPAR␥3-E-box mediate the induction of the PPAR␥ gene by ADD-1/SREBP-1 and SREBP-2. Relative luciferase activity as determined after transfection of CCL39 cells with the reporter constructs pGL3␥1p2000, pGL3␥1p2000-E-box mut , pGL3␥3p800, and pGL3␥3p800-E-box mut . Cells were cotransfected with either an empty expression vector (control) or an expression plasmid for SREBP-1 or SREBP-2. Values are the mean Ϯ standard deviation of three independent experiments. Statistically significant differences (P Ͻ 0.05) by Student's t test are indicated by asterisks. ther inducing expression of a PPRE-driven reporter gene to a similar level in medium with or without sterols (Fig. 7C) . All of this suggests that in the case of PPAR␥, the inhibitory effects of fatty acids might be insufficient to overcome the potent stimulatory effects of cholesterol depletion on PPAR␥ expression or, alternatively, that the addition of fatty acids might have an independent and direct stimulatory effect on PPAR␥ expression. In addition, the absence of PPAR␥ expression in medium with cholesterol ( Fig. 2A and B, lanes 1 and 3) would obscure any further inhibitory effect fatty acids might have on this regulation.
Interestingly, the implications of the control of PPAR␥ expression by the ADD-1/SREBP-1 family of transcription factors and cholesterol may extend beyond the control of adipogenesis and affect total body lipid and glucose metabolism. First, in view of the important insulin sensitization which accompanies PPAR␥ activation in vivo, the regulation of PPAR␥ expression and activity by changes in cellular cholesterol concentration suggests that cholesterol homeostasis could have an impact on whole-body glucose homeostasis. Further in vivo studies exploring this issue are definitely needed. Second, the regulation of the expression of PPAR␥, a nuclear receptor that is activated by fatty acid metabolites, by the cholesterol-regulated transcription factors of the ADD-1/SREBP-1 family, links transcriptional control by these two important classes of lipids. Changes in intracellular cholesterol levels will, via modulation of ADD-1/SREBP-1 and/or SREBP-2 activity (31, 40, 50) , profoundly affect fatty acid and triglyceride metabolism, which is controlled by PPAR␥ activity. One interesting example of such an interrelationship between cholesterol and fatty acid metabolism, is the observation that powerful HMG-CoA reductase inhibitors, such as simvastatin (28) or atorvastatin (1) , not only reduce circulating cholesterol but also reduce triglyceride levels. Whereas the reduction in cholesterol levels could be explained by their inhibitory effect on the key enzyme controlling cholesterol biosynthesis, HMG-CoA reductase, no explanation is available for their beneficial effect on triglyceride levels. Cholesterol depletion induced by these agents, however, leads to proteolytic activation of the ADD-1/SREBP family (31, 40) . If this causes an induction in PPAR␥ levels, as shown here, the increased PPAR␥ transcriptional activity would be expected to induce the expression of several genes involved in triglyceride clearance (for review, see reference 34). Hence, this mode of interaction between transcription factors controlling different lipid pathways may provide an explanation for both the somewhat unexpected triglyceridelowering effects that have been observed when these cholesterol-lowering agents have been used in this therapeutic context and for the pronounced beneficial effects of the statins in patients with diabetic hyperlipidemia. This new knowledge could provide a basis for development of agents which have a broader or more specific ability to regulate different aspects of lipid metabolism.
